Sermorelin

Sermorelin is a growth hormone releaser, a synthetic fragment of growth hormone-releasing hormone (GHRH) that prompts the pituitary gland to release the body's own growth hormone, and it's the structural parent of CJC-1295. It's usually pursued today for anti-aging, sleep, and body-composition effects, though those uses aren't backed by large adult trials. It was approved decades ago, as Geref, for children with growth hormone deficiency, then pulled from the US market for business reasons, not safety; it's now available only through compounding pharmacies, and it's banned in drug-tested sport.

Sermorelin, a GHRH analog that prompts the body's own growth-hormone release, was historically used in childhood growth-hormone deficiency and as a pituitary-function test. In that childhood program, daily sermorelin was reported to increase height velocity. There are no large controlled trials supporting the adult anti-aging, body-composition, and sleep uses that dominate current interest — that use rests on the childhood evidence, the broader GHRH literature, and user reports.

FDA-approved historically as Geref (sermorelin acetate; NDA 019863, EMD Serono / Serono Laboratories) — initially approved December 28, 1990 for diagnostic evaluation of pituitary GH reserve, with broader treatment approvals for pediatric idiopathic growth hormone deficiency added through subsequent label revisions. Voluntarily withdrawn from the US commercial market in 2008 by EMD Serono for commercial / manufacturing reasons, not safety. The FDA officially determined in March 2013 (Federal Register notice) that the GEREF withdrawal was not for reasons of safety or effectiveness — meaning generic and compounded versions of sermorelin can legally re-enter the market under abbreviated regulatory pathways. Currently available via compounding pharmacies in the US for off-label use; FDA-approved branded Geref is not currently marketed. WADA-banned in regulated sport — explicitly listed as *"sermorelin"* under Section S2.2.4 (Growth Hormone Releasing Factors → GHRH and its analogues) of the 2026 Prohibited List, the same subsection as CJC-1293, CJC-1295, and tesamorelin. Not DEA-scheduled.

Sermorelin's FDA-approved branded product was withdrawn in 2008; it is now available only through compounding pharmacies under prescription, and it is banned in regulated sport (WADA). VialWise is a research and educational reference, not medical advice — consult a licensed professional.

⚠️ For research and educational purposes only. Sermorelin (Geref) was FDA-approved historically for pediatric growth hormone deficiency diagnosis and treatment but voluntarily withdrawn from the US commercial market in 2008. It is currently available via compounding pharmacies in the US for off-label use. Information in this entry is informational, not medical advice. Always confirm dose calculations with the in-app calculator and consult appropriate professional guidance before any protocol decisions.

⚠️ Precision matters at low doses. Sermorelin is dosed in micrograms (mcg), not milligrams. Typical research-community doses ( per dose) at typical reconstitution concentrations ( for a vial reconstituted with 2.5–3 mL BAC water) produce small draws in the range on a U-100 syringe. At those draw sizes, even a one-unit error is a meaningful percentage of the dose. Always verify draws against the in-app calculator.

⚠️ Sermorelin is the structural parent of CJC-1295. Sermorelin = GHRH(1-29) — the first 29 amino acids of native GHRH, the shortest synthetic peptide that retains full biological activity at the GHRH receptor. CJC-1295 no-DAC = GHRH(1-29) with four amino-acid substitutions that resist enzymatic degradation by DPP-4 and other proteases (extending half-life from ~10–20 min for sermorelin to ~30 min for CJC-1295 no-DAC). CJC-1295 with DAC = GHRH(1-29) + the same substitutions + an albumin-binding maleimidopropionic acid linker (extending half-life further to ~6–8 days). Mechanistically, all three are GHRH receptor agonists at pituitary somatotrophs producing pulsatile GH release — they differ primarily in stability and dosing frequency, not in receptor target. See [cjc-1295.md](./cjc-1295.md) for the broader GHRH-analog family discussion.

⚠️ FDA-approved historically; currently compounding-pharmacy-supplied. The FDA-approved branded Geref product was withdrawn from the US commercial market in 2008 (voluntary, commercial reasons — not safety; FDA confirmed in March 2013 Federal Register notice that the withdrawal was not for reasons of safety or effectiveness).[³] Sermorelin is currently legally available in the US via compounding pharmacies only — this is a different regulatory framework from the FDA-approved-and-marketed branded products (Genotropin, Xyosted, Egrifta) covered elsewhere in this library. Compounded sermorelin is dispensed under a prescriber's order through a 503A or 503B compounding pharmacy and is legal for the prescribed patient's use; off-prescription supply chains exist but operate outside the compounding-pharmacy regulatory framework.

Sermorelin is the 29-amino-acid N-terminal fragment of native human growth hormone-releasing hormone (GHRH) — specifically GHRH(1-29)NH2, the shortest synthetic peptide that retains full biological activity at the GHRH receptor. Native GHRH is a 44-amino-acid hypothalamic peptide; the discovery that the bioactivity resides entirely within the first 29 amino acids enabled the development of sermorelin as a clinically useful synthetic GHRH analog.[¹] Sermorelin was developed in the late 1980s and FDA-approved as Geref by EMD Serono (originally Serono Laboratories) on December 28, 1990, initially for diagnostic evaluation of pituitary GH reserve and subsequently expanded to treatment of pediatric idiopathic growth hormone deficiency.[¹][²]

Mechanism. Sermorelin binds the GHRH receptor (GHRHR) on pituitary somatotrophs, activating adenylyl cyclase through Gαs protein coupling, increasing intracellular cAMP, and triggering pulsatile GH release. The mechanism is identical to native GHRH — sermorelin's pharmacological identity as a GHRH receptor agonist is exact, distinguishing it from the GH secretagogues (Ipamorelin, MK-677, GHRP-2) that act on the ghrelin receptor at the same target cells. Sermorelin preserves the pulsatile pattern of endogenous GH release — the GH response to sermorelin is subject to somatostatin-mediated negative feedback, which makes sermorelin self-limiting and unable to drive supraphysiologic GH levels (in contrast to exogenous somatropin/HGH, which bypasses pituitary feedback entirely). See [hgh.md](./hgh.md) for the broader exogenous-HGH-vs-secretagogue distinction.

Clinical history. Geref (sermorelin acetate) was FDA-approved in two formulations: - Geref Diagnostic (/amp) — for evaluating pituitary somatotroph capacity to secrete GH (diagnostic GH-stimulation test in suspected pediatric GHD) - Geref ( and base/vial) — for treatment of pediatric idiopathic GHD with growth failure

In the pediatric treatment program, daily sermorelin /day SC at bedtime was reported to produce catch-up growth in the majority of children with idiopathic GHD, with the height-velocity increase sustained over 12 months of treatment and data extending to 36 months in some children.[¹] EMD Serono voluntarily withdrew Geref from the US commercial market in letters dated July 11, 2008 and December 2, 2008 — for commercial/manufacturing reasons, not safety concerns. The FDA's March 2013 Federal Register notice formally determined that the GEREF withdrawal was not for reasons of safety or effectiveness[³] — a regulatory determination that has practical consequence: it permits generic and compounded versions of sermorelin to enter the market under abbreviated regulatory pathways without re-establishing the safety basis of the original approval.

Regulatory status (US — current). Sermorelin is currently available in the US via compounding pharmacies only (503A or 503B compounding pharmacies dispensing under a prescriber's order). The FDA-approved branded Geref product is not currently marketed. This regulatory status is distinct from: - FDA-approved-and-marketed branded products (Genotropin, Xyosted, Egrifta, Vyleesi) — full FDA framework - Unapproved research peptides (CJC-1295, BPC-157, TB-500) — outside FDA approval entirely - DEA-controlled substances (testosterone) — Schedule III - Federally-distribution-restricted drugs (HGH/somatropin) — 21 USC 333(f)

Sermorelin sits in a "previously-FDA-approved-now-compounded" category that is legal for prescribed use but is not currently a commercial pharmaceutical product. Not DEA-scheduled.

Regulatory status (sport — WADA). Sermorelin is explicitly listed under Section S2.2.4 (Growth Hormone Releasing Factors) of the 2026 WADA Prohibited List, in the GHRH-analogues subsection alongside CJC-1293, CJC-1295, and tesamorelin. Verbatim from the canonical PDF: *"growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)."*[⁴] Prohibited at all times.

Common research interests. Despite the FDA market withdrawal, sermorelin is widely used in compounding-pharmacy and research-community contexts for: - Adult "anti-aging" / metabolic optimization — the dominant compounding-pharmacy use case. Marketed as a "natural" alternative to direct HGH that preserves pulsatility. Off-label; no FDA-approved indication for adults. - Body composition / recovery during training cycles — research-community use parallel to CJC-1295 patterns. - Sleep quality — bedtime sermorelin is reported to amplify the natural sleep-onset GH pulse and improve subjective sleep architecture; this is one of the consistently-reported subjective effects across research-community materials. - Adjunct to peptide stacks — sometimes combined with Ipamorelin or other GHRPs for synergistic GH release.

Sermorelin vs CJC-1295 — the practical comparison. This comparison is the most useful framing for researchers selecting between GHRH analogs: - Sermorelin: short half-life (~10–20 min); requires daily bedtime dosing; subject to natural pulsatility and somatostatin feedback; legal via compounding pharmacy; FDA-approved historically. - CJC-1295 no-DAC: similar short half-life (~30 min); also daily; not FDA-approved; available as research peptide. - CJC-1295 with DAC: long half-life (~6–8 days); weekly dosing; sustained baseline GH elevation; not FDA-approved. - Tesamorelin: ~26 min half-life; daily; FDA-approved for HIV-lipodystrophy.

The Sermorelin / CJC-1295 no-DAC comparison is essentially regulatory: both are GHRH(1-29)-based fragments with similar half-lives and similar dosing patterns. Researchers selecting on regulatory clarity (and willing to work through a compounding pharmacy under prescription) will land on sermorelin; researchers selecting on cost and availability will more often land on CJC-1295 no-DAC.

Commonly reported

• Injection site reactions — local pain, redness, mild swelling; daily dosing produces more frequent site exposure than weekly compounds
• Flushing — uncommon but reported; transient, related to acute GH pulse
• Headache — uncommon
• Mild fluid retention / edema — uncommon at typical doses; more common at higher doses or in older patients
• Nausea — uncommon
• Hyperactivity / irritability — reported in pediatric populations historically; rare in adult compounding-pharmacy use
• Thyroid suppression — theoretical concern; rare at typical doses, but T4-to-T3 conversion can be affected by sustained GH elevation
• IGF-1-mediated theoretical cancer concerns — IGF-1 is a known proliferative signal; chronic GH-axis stimulation has been raised as a theoretical concern for individuals with active or undiagnosed malignancy. Same class consideration as HGH, CJC-1295, and tesamorelin.
• Insulin resistance / impaired glucose tolerance — well-documented with sustained exogenous GH and supraphysiologic GH-axis stimulation. Sermorelin's pulsatility-preserving and self-limiting nature makes this risk lower than with exogenous HGH but not zero.
• Long-term safety in adults is essentially unknown — the FDA-approved pediatric program had defined endpoints; adult use over multi-year periods is not characterized in published clinical literature.

Active malignancy — IGF-1 elevation may promote cancer growth

Hypersensitivity to sermorelin, mannitol, or other product components

Pregnancy and lactation — Category C; insufficient human data; default to contraindicated

Disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor) — sermorelin requires intact pituitary somatotroph function

Pediatric use (historical Geref indication): specialist (pediatric endocrinology) supervision required.

Adult use: off-label; no FDA-approved adult indication.

Concurrent corticosteroid use: may interfere with sermorelin's GH-stimulating effect.

Diabetes / impaired glucose tolerance: monitor glucose carefully.

Regulatory note (US): sermorelin is available via compounding pharmacies only in the US currently (FDA-approved branded Geref withdrawn 2008). Off-prescription / non-compounded supply is illegal under federal law.

Regulatory note (sport): sermorelin is explicitly listed in WADA 2026 Prohibited List Section S2.2.4 alongside CJC-1295 and tesamorelin; prohibited at all times in regulated sport.[⁴]

Peptide

A short chain of amino acids, the building blocks of proteins. Many compounds in this library are peptides.

Growth hormone secretagogue

A compound that signals the body to release its own growth hormone, rather than supplying growth hormone directly.

Pituitary gland

A small gland at the base of the brain that releases growth hormone and other hormones.

Compounding pharmacy

a pharmacy that prepares a medication to order under a prescription.

WADA Prohibited List

The list of substances banned in regulated sport by the World Anti-Doping Agency.

1. Prakash A, Goa KL. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, 12(2):139–157.(PMID 18031173)
2. EMD Serono / Serono Laboratories. Geref (sermorelin acetate for injection) prescribing information (historical). US Food and Drug Administration. NDA 019863, originally approved December 28, 1990. Pre-1996 FDA review available at accessdata.fda.gov/drugsatfda_docs/nda/pre96/019863_S001_GEREF.pdf.
3. US Food and Drug Administration. Federal Register notice — Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register, March 4, 2013.
4. World Anti-Doping Agency. The 2026 Prohibited List, International Standard (effective 1 January 2026). Canonical PDF: wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf (linked from the WADA landing page; local archival copy in `docs/legal/wada-2026-prohibited-list.pdf`). Sermorelin is named explicitly under Section S2.2.4 (Growth Hormone Releasing Factors) — the same subsection as CJC-1293, CJC-1295, and tesamorelin. Verbatim from the canonical PDF, page 8: "growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)." Prohibited at all times.
5. Dominikowski A, et al. (2026). The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology (Lausanne), 17:1822475 (published 2026-06-18).(PMID 42395176)

• Ipamorelin — discussed together in this entry's stacks section
• Testosterone — discussed together in this entry's stacks section
• AOD-9604 — discussed together in this entry's stacks section
• BPC-157 / TB-500 Blend — discussed together in this entry's stacks section
• CJC-1295 / Ipamorelin Blend — same mechanism class
• CJC-1295 — same mechanism class